What Нооклерин Treats: Main Uses and Benefits

The primary therapeutic role of Нооклерин (Deanoli Aceglumas) is relevant when supportive symptom management is appropriate across clinical situations where the central nervous system's function is affected by exhaustion or disorder. Its application aligns with therapeutic principles discussed in medical literature.

Targeting Fatigue and Functional Support

The medication may assist with managing conditions characterized by periods of heightened symptoms of persistent, debilitating fatigue, often referred to as asthenic syndrome, alongside reductions in mental and motor activity. It is commonly used to help with symptom clusters that may become intense or disruptive, and contributes to easing the overall symptom load. It is relevant for easing symptoms linked to organ-specific functional stress caused by sustained strain. It is also considered relevant for supporting symptoms that interfere with daily functioning, such as those related to concentration, learning, and memory impairment.

Adjunctive Support in Specific Clinical Scenarios

Нооклерин is applied in clinical settings that involve acute or unstable symptom patterns and is relevant when supportive symptom management is appropriate. This includes its use in the complex symptomatic management during alcohol withdrawal syndrome, where it provides support that helps ease the overall symptom burden. It is also considered relevant for the symptomatic management of associated tension and sleep disturbances in certain neurological presentations like tension-type headache in children.

---

Quick Fact: Focus on Symptom Clusters
This medication is commonly used to help with symptom clusters that may become intense or disruptive, supporting patients during episodes of heightened discomfort.

Who can and cannot use Нооклерин (Deanoli Aceglumas)

Official regulatory documents define strict criteria for patient eligibility and non-eligibility for Нооклерин. Use is generally permitted for adults and children 10 years of age and older, provided no contraindications are present.

Absolute Contraindications

The medicine is strictly contraindicated and must not be used in the following populations or clinical states:

• Pediatric Age: Children younger than 10 years of age.
• Hypersensitivity: Individuals with known allergy or hypersensitivity to any component.
• Reproductive Status: Individuals who are pregnant or breastfeeding (lactating).
• Organ Function: Patients with severe impairment of liver function or severe impairment of kidney function.
• Comorbidities: Patients with diseases of the blood system, infectious diseases of the Central Nervous System (CNS), febrile states, or psychotic states.

Condition-Based Restrictions

Use of the medicine requires caution in patients with less severe, non-expressed impaired liver function or impaired kidney function.

The official interaction profile for Нооклерин (Deanoli Aceglumas) is derived exclusively from information explicitly documented in government regulatory sources, such as official prescribing labels and national regulatory monographs. A comprehensive review indicates that the available regulatory documentation does not specify any concrete interaction entities across key pharmacological domains.

Interaction Category	Regulatory Status
Documented Contraindications	None explicitly listed in relation to drug interaction risk.
Pharmacokinetic Interactions (CYP, Transporters)	No specific effects on Cytochrome P450 (CYP) enzymes or drug transporters are documented.
Timing & Administration Constraints	No mandatory dose separation or administration timing requirements are specified.
Food, Alcohol, Herbal Interactions	No formal restrictions or statements concerning co-administration with these products are documented.

Due to this status, the official regulatory profile is characterized by the absence of specific regulatory statements defining drug-drug, metabolic, or timing-based constraints. The official labeling for Deanoli Aceglumas does not list any formally prohibited combinations that require restriction. The structure of this section is based on the official determination that no specific, clinically significant interactions have been documented that necessitate formal restrictions or warnings in the regulatory filing.

Modulating Signal Transduction in Target Receptor Systems

Нооклерин acts primarily as a modulator within defined central receptor systems, influencing the sensitivity and response of key neural proteins. This action involves either a direct binding to the receptor site or an allosteric adjustment of the receptor’s structure, which alters its affinity for endogenous neurotransmitters. Adjustment of the receptor response at the molecular level contributes to reduced hyper-excitability and diminished signaling within the central nervous system.

Influencing Neural and Humoral Pathways

The initial receptor interaction triggers a subsequent adjustment in the signaling dynamics of broader neural and humoral pathways. This involves downstream effects on secondary messengers and key regulatory systems. The modulation affects pathways characterized by heightened signaling or flux, influencing activity levels within related regulatory systems. This mechanistic domain contributes to altering internal physiological processes that may display irregular activity patterns.

Modifying Mechanistic Neuro-Regulation

The mechanism operates within molecular cascades that involve regulatory feedback loops essential for influencing neural homeostasis. This action is categorized as mechanism-driven modulation of signal transduction, targeting the transmission and regulation of signals to modify functional balance. Engagement of regulatory mechanisms limits the downstream impact of persistent over-signaling, reducing the influence of dysregulated mediators. The final physiological consequence is the functional adjustment of neuro-regulation, modifying activity patterns within core neurological processes.

How to Use Нооклерин: Official Administration Guidelines

Нооклерин (Deanoli Aceglumas) is administered via the oral route as a 20% solution (1 g active substance per 5 mL). The standard usage protocol is defined by specific dosing ranges and a required cyclical schedule.

Administration Protocol

The daily dose is generally administered in two to three divided administrations throughout the day. A critical constraint is that the final daily dose must be taken no later than four hours before the patient's intended bedtime.

Administration is generally independent of meal times, and the solution is taken orally, often with water. The regimen does not require any preparation steps, such as dilution or reconstitution, as it is a ready-to-use liquid.

Dosage and Duration

For adults, the typical starting dose is 1 g (5 mL) per day, ranging up to a maximum daily dose of 10 g (50 mL) in specific circumstances. The treatment is conducted in defined courses (cycles). A standard course of administration lasts approximately 1.5 to 2 months.

Age-Specific Administration: Pediatric and geriatric use involves specific regimens. Dosing for geriatric patients often begins at a lower initial dose, such as 0.5 g daily, with any increase requiring cautious and gradual titration. For children, a specified regimen begins at 0.5 g daily, increasing depending on the age group. The protocol also requires a mandatory interval, typically 1 to 6 months, before any course of the medicine may be repeated, establishing the intermittent use pattern.

If a dose is missed, subsequent doses should not be doubled or combined; the standard schedule should be resumed immediately.

Research Evidence / Overview of Studies for Нооклерин (Deanoli Aceglumas)

Evidence for Use in Asthenic and Cognitive Disorders

This section will summarize the structure of available short-term randomized and comparative studies that examined the medicine's role in combined treatment protocols for asthenic (fatigue) and cognitive symptom clusters in specific adult and young adult populations.

Research examined how symptoms change over time in adults and young adults facing conditions associated with periods of heightened symptoms. Studies focused on evaluating the medicine when applied in research contexts involving fluctuating or unstable symptoms, particularly when it was observed in a combined therapeutic approach alongside existing psychopharmacological treatment. The primary outcomes related to systemic or functional imbalance were measured using specialized scales tracking patient-reported outcomes describing perceived discomfort and functional decline. The findings describe patterns observed in the studies over observation periods of about 30 days. Sample sizes were modest, and follow-up durations were limited.

Evidence for Use in Alcohol Withdrawal Syndrome

The medicine was studied for its application in research contexts involving fluctuating or unstable symptoms, specifically in adult patients experiencing acute alcohol withdrawal syndrome (AWS). Research examined temporary physiological imbalance during the acute phase. Outcomes related to episodic or acute changes were captured using standardized clinical tools. Findings describe patterns observed in the studies related to the measured severity of withdrawal symptoms during the study period. There is limited information for long-term patterns concerning issues like relapse prevention or sustained function after the acute phase.

Evidence for Use in Sleep Disturbances in Specific Pediatric Populations

Research was evaluated in children and adolescents (aged 9 to 16 years) who presented with sleep disturbances associated with a tension-type headache (TTH) diagnosis. The studies were designed as a randomized, placebo-controlled format, monitoring changes over defined time intervals. Evidence is limited, as the available data primarily stem from a single focused randomized controlled trial. Certainty remains low, and results apply only to the populations studied—children with TTH-related sleep issues.

What Is Still Uncertain About Нооклерин Research

Data are still emerging, and long-term patterns are not fully established for any indication. Follow-up durations were limited in most available studies. Gaps in knowledge remain regarding the generalizability of findings and long-term functional and cognitive patterns.

Common questions about Нооклерин (FAQ)

Q: What is the main medical condition Нооклерин is officially approved to treat?

Official regulatory documents indicate the medicine is intended for use in conditions linked to asthenic (fatigue) and cognitive symptom clusters. Its approved uses also include providing support in specific acute states, such as alcohol withdrawal syndrome.

Q: Are there any known long-term safety concerns officially associated with Нооклерин use?

Regulatory reviews mention that the research studies conducted had limited follow-up durations. Because of this, official information states that long-term patterns of safety are not fully established for this medicine.

Q: What official safety classifications (e.g., pregnancy category) does Нооклерин have?

Official safety information specifically contraindicates the use of Нооклерин in individuals who are pregnant or breastfeeding (lactating). This constraint is established in regulatory documents covering its use in special populations.

Q: How recent is the main body of research evidence on Нооклерин?

The body of published scientific literature cited in the official drug documents includes research dating as recently as 2017. However, regulatory reviews also describe the evidence base on long-term effects as emerging, suggesting research is still growing.

Q: What do regulatory bodies state about the evidence for Нооклерин's effectiveness?

Official product information describes the evidence base for the drug as primarily derived from short-term randomized studies. It indicates that, for some specific populations studied (such as children with TTH-related sleep issues), the certainty of the available evidence remains low.

Q: Is the full mechanism of action of Нооклерин completely understood by researchers?

Official documentation describes the mechanism of action in detail, explaining that the medicine acts as a modulator of central receptor systems to adjust neuro-regulation. However, the official label does not include a final statement on whether the mechanism is considered completely understood by researchers.

Q: How long does it usually take to feel the initial effects of Нооклерин?

The official regulatory label does not specify a perceived time when patients should feel the initial effects of the drug. Details on absorption and elimination are provided within the pharmacokinetic profile of the medicine.

Q: Do the effects of Нооклерин build up over several days or weeks of use?

The official label does not describe a specific period for the gradual buildup of effects (steady state). The typical treatment is established as a defined course of administration lasting approximately 1.5 to 2 months.

Q: What is the typical duration of effect after a single prescribed use?

Official documents do not specify a fixed duration of action after a single dose. However, the approved administration protocol requires that the final daily dose must be taken no later than four hours before the patient's intended bedtime.

Q: Is Нооклерин safe for people who have hypertension?

The official regulatory label does not include hypertension (high blood pressure) as an absolute contraindication or a specific condition requiring caution.

Q: Has Нооклерин been studied for uses beyond its primary approved indications?

The available research evidence summarizes studies conducted across several different contexts. These include examining the medicine's role in asthenic disorders, management in alcohol withdrawal syndrome, and pediatric sleep disturbances in specific populations.

Q: Does Нооклерин require a prescription in most countries where it is available?

In the jurisdiction of its primary regulatory approval, the medicine is legally classified as a prescription drug. This official classification status is noted in the regulatory monograph.

Q: How is the drug Нооклерин eliminated from the body according to pharmacokinetic studies?

Official pharmacokinetic studies detail the fate of the medicine in the body. The label provides information regarding the metabolism and elimination pathways of the active ingredient, Deanoli Aceglumas, from the body.

Q: Why does the official documentation mention not combining Нооклерин with MAO inhibitors?

The official regulatory profile for Нооклерин is characterized by an absence of specific regulatory statements defining drug constraints. The official documentation, therefore, does not list any formally prohibited combinations, including specific mention of MAO inhibitors.

Q: What is the meaning of the generic name for Нооклерин?

The active ingredient's chemical name is Deanoli Aceglumas. This name is derived from its two main components: Deanol and N-ацетил-L-глутаминовая кислота (Aceglumate).

How to Store and Dispose of Нооклерин (Deanoli Aceglumas)

Official regulatory labeling dictates strict conditions for the storage and disposal of Нооклерин (oral solution) to maintain its stability.

Storage Requirements

• Temperature: Store at a temperature not exceeding 25 C (77 F). The product must not be frozen.
• Protection: The solution must be kept in a dry place and protected from light.
• Packaging: Store the medicine in its original primary packaging.
• In-Use Stability: After opening the vial, the solution must be used within 1 month.
• Child Safety: The product must be stored out of the reach and sight of children.

Disposal Instructions

Expired or unused Нооклерин must be disposed of in accordance with local pharmaceutical regulations. Disposal procedures should adhere to established guidelines for medicinal product waste.